ACR Meeting Abstracts

ACR Meeting Abstracts

Session » Rheumatoid Arthritis-Small Molecules, Biologics and Gene Therapy V: Immunogenecity

Date: Tuesday, November 10, 2015

Time: 2:30PM-4:00PM

Meeting: 2015 ACR/ARHP Annual Meeting

Abstract Number: 3110
In the Multicenter Randomized Controlled Rotation or Change Trial, a Non-TNF Targeted Therapy Has a Higher Efficacy Than a Second Anti-TNF at 3, 6 and 12 Months
Abstract Number: 3111
Long-term Safety and Efficacy of Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor-α (GM–CSFR-α) Monoclonal Antibody, in Patients with Rheumatoid Arthritis (RA)
Abstract Number: 3112
Incidence of Anti-Drug Antibodies in Rheumatoid Arthritis Patients Treated with Adalimumab, Etanercept, or Infliximab in a Real-World Setting
Abstract Number: 3113
Interest of Assessing Anti-Drug Antibodies  for the Choice Between a Second Anti-TNF and a Non-TNF-Targeted Biologic in Patients with Inadequate Response to a First Anti-TNF : Results from the Randomized Controlled Trial « Rotation or Change »
Abstract Number: 3114
Immunogenicity of Subcutaneous and Intravenous Tocilizumab As Monotherapy or in Combination with Dmards
Abstract Number: 3115
Autoantibodies of the IgA Type a Link Between the Gut and the Anti-TNF Therapy Response in Rheumatoid Arthritis Patients Analysed in Two Clinical Trials

« View all sessions from this meeting